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were identified. Patients were required to have ≥ 365 day of continuous enrollment 
prior to and ≥ 730 days after the index date (date of the first claim), a claim with a 
T2DM diagnosis (ICD-9-CM 250.x0, 250.x2) and no claims for a DPP-4i medication 
prior to the index date. All-cause and diabetes-related total costs were captured over 
one-year and two-year follow-up periods. Generalized linear models with log link 
and gamma distribution were fit to compare costs between the two cohorts, control-
ling for patient baseline characteristics. Results: The final sample comprised 3,354 
saxagliptin initiators and 26,895 sitagliptin initiators. The average age of saxagliptin 
and sitagliptin initiators was 57 years old and just over 50% were males. After adjust-
ing for baseline characteristics, saxagliptin patients had significantly lower average 
all-cause medical costs over the one-year ($8,406 vs. $9,368, p< 0.0001) and two-year 
follow-up ($17,367 vs. $19,410, p< 0.0001) compared with sitagliptin patients. Total 
costs were lower for saxagliptin initiators over the one-year ($13,644 vs. $14,388, 
p= 0.0015) and two-year follow-up ($27,491 vs. $29,198, p= 0.0002). Findings were 
consistent for diabetes-related medical costs (one-year: $2,097 vs. $2,370, p< 0.0001; 
two-year: $4,312 vs. $4,753, p= 0.0003) and total diabetes-related costs (one-year: 
$4,210 vs. $4,417, p= 0.0048; two-year: $8,391 vs. $8,701, p= 0.0326). ConClusions: 
Initiation of treatment with saxagliptin was associated with lower medical costs 
over one and two years compared with sitagliptin.
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objeCtives: Portfolio management is commonly used to prioritize investments 
within the private sector, but is not used widely to manage public research invest-
ments due to the difficulty of defining and quantifying appropriate measures 
of risk and return. We recently developed a novel tools to estimate the risk and 
return of publicly funded cancer clinical trials. Our objective was to use these 
metrics and apply a proof of concept portfolio management approach within 
SWOG, a large cancer clinical trials cooperative group. Methods: The sample 
portfolio included 9 randomized Phase II/III clinical trial concepts reviewed by 
SWOG between 2008-2013, of which 5 were approved and 4 were not. Risk was 
defined as the probability of insufficient accrual (< 50% of target) and measured 
using a previously validated prediction model. Value of Information methods were 
used to estimate societal return, defined both as the population-level expected 
health benefits (clinical return) or clinical and economic benefits (net return) of 
acquiring additional information to inform a decision and measured. We com-
pared the risk-adjusted expected returns of the observed portfolio of approved 
trials to hypothetical alternative portfolios in which different trials might have 
been funded. Results: The clinical return of SWOG’s sample portfolio was valued 
at $11.3 billion. A hypothetical alternative portfolio of trials requiring 200 fewer 
patients than the observed portfolio was expected to have a clinical return of $26.3 
billion. The net return of SWOG’s observed sample portfolio was $2.7 billion. An 
alternative hypothetical portfolio that includes four trials and requires 400 fewer 
patients than the observed portfolio was expected to have a net return of approxi-
mately $9.6 billion. ConClusions: A portfolio management approach appears 
to be a feasible and potentially useful response to the Institute of Medicine’s call 
for more systematic approaches to prioritize trials concepts within the cancer 
clinical trials cooperative groups.
HEaltH tECHnOlOgY assEssmEnt stUDiEs
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objeCtives: Ultra orphan therapies are indicated for rare diseases affecting less 
than a few thousand patients. The annual and lifetime per patient cost of these 
treatments have generated controversy and policy questions regarding cost effec-
tiveness and reimbursement. The objective of this analysis was to review all avail-
able cost effectiveness studies and develop lessons for policy development for ultra 
orphan therapies. Methods: Fifteen European Medicines Agency (EMA) and Food 
and Drug Administration (FDA) approved ultra orphan drugs were identified and 
reviewed for their published cost effectiveness through studies in peer-reviewed 
journals and Health Technology Assessments (HTAs). Data was collected for: (1) 
Product (2) Indication (3) Model design and assumptions (4) Author of the analy-
sis (manufacturer, HTA or academic group) (5) Cost effectiveness results and (5) 
Sensitivity analysis results. All cost effectiveness ratios were converted to 2013 US 
dollar amounts using historical currency conversion rates. Results: For fifteen 
EMA and FDA approved ultra orphan therapies, eight cost effectiveness studies 
were identified for seven products (50%). Four of these studies were conducted by 
the sponsor (as part of the HTA submission), two were conducted by HTAs and two 
were from academic groups. All models were developed for a life time horizon. 
In the base case scenario, the median base case incremental cost effectiveness 
ratio (ICER) was $591,200 per quality adjusted life years (QALYs) (range: $391,120 
to $7,425,000). The sensitivity analyses results had a median ICER of $1,958,674 per 
QALY, with a maximum ICER of $10,395,000. All reported ICERs exceeded the maxi-
mum accepted thresholds for end of life care therapies. ConClusions: Review of 
cost effectiveness studies for ultra orphan therapies shows that none were able to 
show ICERs within typical thresholds. These results suggest a need for new policy 
regarding acceptable threshold, or type of models for assessing the cost effective-
ness of ultra orphan therapies.
patient costing), more details on the various cost components and sources of 
data, and considerations for costing based on economic evaluation considera-
tions (e.g. setting, perspective). ConClusions: The 2nd edition of the Guidance 
Document aims to better assist Canadian researchers in appropriately identifying, 
measuring, and sourcing the types of costs and resources relevant for economic 
evaluations.
HEaltH CarE EXpEnDitUrE stUDiEs
HE1
HEaltH CarE rEsOUrCE UtilizatiOn amOng mEDiCarE bEnEfiCiariEs 
witH COpD: COmparisOn Of HigH anD lOw UtilizErs
Xu X., Rao Y., Miyasato G.
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objeCtives: The Centers for Disease Control and Prevention reported that the costs 
attributable to Chronic Obstructive Pulmonary Disease (COPD) are projected to be 
$49.0 billion by 2020. This retrospective claims analysis characterized and compared 
Medicare beneficiaries with high and low healthcare resource utilization (HCRU) as 
a means to inform the drivers of this large economic burden. Methods: Medicare 
beneficiaries with a COPD diagnosis in 2012 were identified in the Centers for 
Medicare and Medicaid Services (CMS) claims databases. HCRU groups were defined 
based on the total payment amount across the inpatient, outpatient and physician 
office settings; high and low utilizers represented the top and bottom quartiles, 
respectively. The utilization groups were compared across patient demographics, 
comorbidities and HCRU using t-tests. A classification tree was fitted to identify the 
patient risk factors that were the biggest drivers of differences in HCRU. Results: 
Overall, 257,752 COPD patients were identified, with 64,438 patients in each of 
the high and low utilization groups. The mean (95% confidence interval) payment 
amounts for high and low utilizers were $54,176 ($53,847, $54,506) and $1,131 ($1,126, 
$1,136), respectively. On average, high utilizers had a significantly (p< 0.001) higher 
number of claims, longer length of stay, higher Charlson Comorbidity Index (CCI) 
score and more complicated comorbid respiratory conditions and medical proce-
dures (102, 19, 6, 60%, 21%) relative to low utilizers (16, 0, 2, 23%, 4%). The classifica-
tion tree identified the most important risk factors in differentiating high and low 
utilizers as CCI score, comorbid anemia, COPD complexity, comorbid pneumonia 
and heart failure. ConClusions: HCRU among COPD Medicare patients varied 
greatly, with high utilizers tending to be sicker across all comorbidity measures. The 
classification tree analysis indicated that comorbidities such as anemia, pneumonia 
and heart failure are more highly associated with HCRU than demographic factors, 
such as age, gender and race.
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objeCtives: This study compared home healthcare use and expenditures 
among elderly Medicare beneficiaries with and without Parkinson’s disease 
(PD) and analyzed the extent to which individual-level factors contribute to 
the excess home healthcare use and expenditures among individuals with 
PD. Methods: A retrospective, observational, cohort study was conducted using 
Medicare 5% sample claims database with baseline (year 2006) and follow-up 
(year 2007) period. The study sample included elderly (age > 65 years) fee-for-
service Medicare beneficiaries continuously enrolled in Medicare Part A and B for 
2006 and 2007. Elderly Medicare beneficiaries with PD were identified based on 
the ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical 
Modification) codes of 332.xx during baseline. All the independent variables were 
measured during baseline. The dependent variables (home healthcare use and 
expenditures) were measured in 2007. Logistic regressions and Ordinary Least 
Square regressions were used to assess the association of PD with home health 
use and expenditures respectively. Post regression non-linear and linear decom-
position techniques were used to understand the extent to which differences 
in home healthcare use and expenditures among elderly Medicare beneficiar-
ies with and without PD can be explained by individual-level factors. Results: 
Elderly Medicare beneficiaries with PD had 13.3 percentage point higher home 
healthcare use, of which 27.5% were explained by differences in characteristics 
between the two groups. Among home healthcare users, those with PD had greater 
expenditures ($6,792) compared to those without PD ($4,965). Only 18% of the 
difference in home healthcare expenditures were explained by differences in 
characteristics between the two groups. Baseline resource use and comorbidi-
ties explained majority of the differences in home healthcare use and expendi-
tures. ConClusions: These findings underscore the importance of developing 
interventions such as using appropriate evidence based co-management of multi-
ple chronic conditions and need of interdisciplinary team collaboration to provide 
better care.
HE3
lOng-tErm HEaltH CarE COsts amOng aDUlts witH tYpE 2 DiabEtEs 
initiating Dpp-4 inHibitOrs
Farr A.M.1, Sheehan J.2, Brouillette M.1, Smith D.M.1, Johnston S.1, Kalsekar I.3
1Truven Health Analytics, Bethesda, MD, USA, 2AstraZeneca, Fort Washington, PA, USA, 
3AstraZeneca, Wilmington, DE, USA
objeCtives: To compare all-cause and diabetes-related utilization and costs fol-
lowing initiation of the dipeptidyl peptidase-4 inhibitors saxagliptin or sitagliptin 
in the treatment of type 2 diabetes (T2DM). Methods: Patients aged 18+ with ≥ 1 
prescription claim for saxagliptin or sitagliptin between 1/1/2009 and 1/31/2012 in 
the Truven Health MarketScan Commercial and Medicare Supplemental databases 
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lations, or comparable study arms preventing a complete assessment of whether 
sub-indications of an anti-diabetic drug provided an “added benefit” to patients. 
Future clinical development plans should include well-designed comparative stud-
ies to improve likelihood of reimbursement and patient access.
patiEnt prEfErEnCE stUDiEs
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patiEnts’ anD pHYsiCians’ timE traDE-Off prEfErEnCEs fOr aDvErsE 
OUtCOmEs assOCiatED witH mEtastatiC COlOrECtal CanCEr 
trEatmEnts
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objeCtives: To estimate health-state utilities for adverse outcomes associated 
with metastatic colorectal cancer. Methods: Patients and physicians completed 
time trade-off (TTO) questions. Health states were drafted and refined based on 
literature review, and patient and clinician interviews. Four adverse conditions 
were described: severe papulopustular rash (rash), serious bleeding, severe heart 
attack, and gastrointestinal perforations. Respondents evaluated the risk of serious 
bleeding, heart attack, and gastrointestinal perforation. Three event risk levels were 
randomized across events and respondents. Rash was presented as a deterministic 
outcome, so respondents evaluated the impact of experiencing the rash, not as a 
‘risk’ of developing rash. Patients and physicians evaluated the health states in 
TTO questions that provided a range of time in the adverse health that would leave 
respondents indifferent between the adverse health states and shorter life spans 
with perfect health. TTO data were analyzed using an interval regression model to 
estimate the health-state utility for each side effect. Results were used to infer the 
health-state utility of the outcomes’ clinically relevant levels corresponding with 
the most commonly used targeted treatments for mCRC, VEGFi and EGFRi (20% 
chance of rash, 5% chance of serious hemorrhage, and a 2% chance of gastrointes-
tinal perforations and cardiopulmonary arrest). Results: A total of 127 patients 
and 150 physicians completed the TTO questions. Among clinically-relevant levels 
of the health states for patients, cardiopulmonary arrest had the lowest utility 
(0.68), with serious hemorrhage (0.74), GI perforation (0.79) and rash (0.91) hav-
ing higher levels of utility. Utility scores for physicians followed a similar pattern: 
cardiopulmonary arrest (0.75), serious hemorrhage (0.76), GI perforation (0.82) and 
rash (0.92). COnClUsiOns: Results add to previously published literature regarding 
utilities for adverse outcomes from patients’ and physicians’ perspectives. Results 
show that patient and physician ratings of health states were largely consistent, 
suggesting agreement in the perceived impact of these adverse events.
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patiEnt prEfErEnCEs fOr first-linE maintEnanCE trEatmEnts fOr 
Ovarian CanCEr
Mansfield C.A.1, Poulos C.1, Hackshaw M.D.2, Pugh A.1, Jobanputra M.H.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline, Philadelphia, PA, USA
objeCtives: Elicit medicine preferences of women eligible to receive first-line 
maintenance treatment for ovarian cancer and estimate benefit-risk trade-
offs. Methods: Women in the United States with self-reported physician diag-
noses of ovarian cancer and eligible for maintenance therapy completed an online 
discrete-choice experiment (DCE) survey. The survey presented nine choice ques-
tions, each including a pair of hypothetical medicine profiles with varying effi-
cacy, tolerability, and risks of side effects. Each profile was defined by the following 
attributes identified from the literature with clinical input and tested in patient 
interviews: progression-free survival (PFS), fatigue, diarrhea, nausea and vomiting, 
hypertension, and risk of gastrointestinal (GI) perforation. The profiles in the choice 
questions were based on an experimental design with known statistical properties. 
Random-parameters logit was used to estimate preferences. Results: Two hundred 
women completed the survey; median age was 49 years, 26% were late stage (3/4), 
and 44% had been diagnosed within 2 years. Across the attributes, better outcomes 
were significantly preferred to worse outcomes, except that respondents did not 
distinguish between no nausea and mild nausea. Relative to the other attributes 
and levels, respondents placed the greatest weight on avoiding severe diarrhea, 
followed by reducing the risk of GI perforation, and increased PFS. Respondents 
were willing to give up 6.5 months of PFS to reduce diarrhea from severe to none. 
No statistical differences were found between the overall preferences of early versus 
late stage respondents, respondents above and below the median age in the sample, 
and respondents who had been diagnosed in the last 2 years compared to those 
diagnosed more than 2 years ago. ConClusions: Women with ovarian cancer were 
willing to trade-off efficacy (PFS) for improvements in side effects and risk. The lack 
of differences across subgroups suggest consistent preferences across the attributes 
within our sample. Funded by GSK.
pp3
patiEnt vErsUs gEnEral pOpUlatiOn prEfErEnCEs in antiCOagUlant 
tHErapY
Najafzadeh M., Gagne J.J., Choudhry N.K., Polinski J., Avorn J.L., Schneeweiss S.
Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
objeCtives: Relative preference weights for outcomes of anticoagulant therapy 
can be used to inform quantitative benefit-risk analyses. Whether patients with 
cardiovascular diseases (CVD) and the general population have different preferences 
for benefits and risks of anticoagulant therapy is unknown. Using a Discrete Choice 
Experiment (DCE), we elicited and compared anticoagulant treatment outcomes 
preferences between patients and the general population. Methods: A sample of 
patients with CVD and a general US population sample were selected from online 
panels. A DCE questionnaire was designed and administered to elicit preferences 
for benefits and risks. Seven attributes described hypothetical treatments randomly 
Ht2
appliCatiOn Of COst-EffECtivEnEss lOgiC tO Us managED CarE DrUg 
fOrmUlariEs: lOng tErm OUtCOmEs Of a valUE-basED fOrmUlarY
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objeCtives: Cost-effectiveness analysis (CEA) is explicitly used for informing drug 
coverage decisions in many countries but not in the United States. Evidence suggests 
that failure to incorporate value considerations in coverage decisions may lead to 
reduced economic efficiency in the form of increased costs or worsened health 
outcomes. Yet the use of CEA in the context of binary coverage decisions (yes or 
no) may not be politically or socially feasible in the US. In 2010, Premera Blue Cross 
implemented a value-based formulary (VBF) that uses CEA to determine the copay-
ment level-not binary coverage-for each drug in the formulary; drugs with lower 
incremental cost-effectiveness ratios (ICERs) are assigned lower copayments, drugs 
with higher ICERs are assigned higher copayments. The objective of this study is to 
assess the impact of Premera’s VBF on healthcare costs and outcomes. Methods: 
We utilize an interrupted time series design with concurrent control group in order 
to examine the impact of the VBF on both pharmacy and medical costs for enrollees 
and the health plan separately and to examine the impact of the VBF on both emer-
gency department visits and acute hospitalizations. In order to accomplish these 
aims, we utilize segmented regression models with two-part generalized estimating 
equations for analysis. Results: Preliminary descriptive analysis suggests that over 
the 4 years of observation, comparing the period before VBF implementation to the 
period after VBF implementation, both medical and pharmacy costs increased more 
in the control group ($38.37 and $4.79 per member per month (PMPM)) than in the 
VBF group ($3.16 and -$0.54 PMPM). The number of emergency department visits and 
acute hospitalizations did not change in either group. ConClusions: Preliminary 
analyses suggest that the use of cost-effectiveness principles in the US context may 
lead to greater economic efficiency. Subsequent analyses utilizing greater control for 
confounding will establish more valid estimates of outcomes and costs.
Ht3
analYsis Of niCE DrUg tECHnOlOgY appraisals (2001-sEptEmbEr 2014)
Briceno V, Seoane-Vazquez E
MCPHS University, Boston, MA, USA
objeCtives: The UK National Institute for Health and Care Excellence (NICE) pro-
vides guidance and advice to improve health care in the UK. This study assessed 
the NICE Drug Technology Appraisals published in the period 2001-September 
2014. Methods: The list of NICE guidance, including published guidance, in 
development and consultations was extracted from NICE webpage. Descriptive 
statistics and chi-square were used in the analysis. Results: In September 2014, 
NICE listed 994 guidance documents, including 246 technology appraisals (TA), of 
which 207 were drug TA. The drug TA assessed 158 different drugs, combinations, 
or drug classes. 75.8% of the drug TA evaluated was recommended by NICE in the 
National Health Service (NHS), however 17.0% of them were not recommended. NICE 
was unable to recommend them because no evidence submission was received 
from the drug sponsor in 7.2% of the TA. In 46.2% of the 91 TA published in 2010-
Sep 2014 and recommended by NICE, the sponsor agreed a patient access scheme 
with the Department of Health to provide a confidential discount. The percent-
age of TA resulting in drugs with indications recommended by NICE decreased 
over time from 89.5% (n= 49) in 2001-2004, to 71.7% (n= 91) in 2005-2009, and 75.8% 
in 2010-September 2014 (p< 0.001). There were six therapeutic classes with 10 or 
more TA: Cancer (68 TA, 57.4% recommended by NICE), blood and immune sys-
tem conditions (27, 77.8%), cardiovascular conditions (20, 95.0%), musculoskele-
tal conditions (16, 81.3%), infections (11, 90.9%), and neurological conditions (10, 
90.0%). ConClusions: Most of the TA resulted in a positive recommendation by 
NICE for using the drug in the NHS. Oncology and blood and immune system condi-
tion had the lowest percentage of TA resulting in a positive evaluation from NICE. 
Over 45% of the TA published after 2010 resulted in a confidential discount provided 
by the sponsor company to the NHS.
Ht4
iqwig EarlY bEnEfit assEssmEnts Of tYpE 2 DiabEtEs tHErapiEs
Oehrlein EM, Hanna ML, Perfetto EM
University of Maryland, School of Pharmacy, Baltimore, MD, USA
objeCtives: Since 2011, the Institute for Quality and Efficiency in Health Care 
(IQWiG) has awarded very few anti-diabetic therapies an “added benefit” over 
current standard therapies status. IQWiG dossier evaluations were examined to 
determine if new therapies do not demonstrate “added benefit” or if results may 
be due to a lack of comparative evidence. Methods: Results from IQWiG dossier 
assessments for all anti-diabetic drug therapies requiring early benefit assessment 
were examined. IQWiG’s website was searched for “diabetes,” identifying Albiglutide, 
Canagliflozin, Dapagliflozin, Empagliflozine, Linagliptin, Lixisenatide, Saxagliptin, 
Sitagliptin, and Vildagliptin. Dossier assessment results were reviewed for all sub-
indications to determine if added benefit had been evaluated. Results: In total, 14 
dossier assessments (9 monotherapies; 5 combination therapies) were reviewed rep-
resenting a total of 48 sub-indications. Of the 48 sub-indications, 2 were designated 
as having “added benefit” or “hint of added benefit,” the remaining 46 did not. The 
most common reasons for no evidence of “added benefit” were: no evidence sub-
mitted (n= 13) or evidence deemed irrelevant (n= 33). The most common reasons for 
supporting studies being deemed irrelevant included: differing “therapeutic strate-
gies” in study arms (n= 4); deviation from G-BA recommended comparator (n= 6); 
lack of power to demonstrate added benefit (n= 1); non-compliance with approved 
dosage (n= 12); non-compliance with approved population (n= 12); insulin therapy 
not tailored to patient (n= 6); study duration too short (n= 5). ConClusions: In most 
cases, the evidence needed to perform an IQWiG early benefit assessment for drug 
therapies for Type II Diabetes did not exist. Moreover, studies with the potential to 
provide the appropriate evidence lacked use of approved dosage, indicated popu-
